{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,29]],"date-time":"2026-04-29T16:37:28Z","timestamp":1777480648574,"version":"3.51.4"},"reference-count":151,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2008,4,1]],"date-time":"2008-04-01T00:00:00Z","timestamp":1207008000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Clinical Densitometry"],"published-print":{"date-parts":[[2008,4]]},"DOI":"10.1016\/j.jocd.2008.02.002","type":"journal-article","created":{"date-parts":[[2008,4,3]],"date-time":"2008-04-03T08:34:04Z","timestamp":1207211644000},"page":"325-338","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":91,"title":["Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases"],"prefix":"10.1016","volume":"11","author":[{"given":"Pierre D.","family":"Delmas","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jocd.2008.02.002_bib1","unstructured":"Osteoporosis prevention, diagnosis, and therapy. NIH Consensus Statement Online. March 27\u201329, 2000 17:1\u201336."},{"key":"10.1016\/j.jocd.2008.02.002_bib2","first-page":"50","article-title":"Contribution of bone mineral density and bone turnover markers to the estimation of risk of osteoporotic fracture in postmenopausal women","volume":"4","author":"Garnero","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.jocd.2008.02.002_bib3","series-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","article-title":"Chapter 2: The basics of bone health and disease","author":"U.S. Department of Health and Human Services","year":"2004"},{"key":"10.1016\/j.jocd.2008.02.002_bib4","series-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","article-title":"Chapter 5: The burden of bone disease","author":"U.S. Department of Health and Human Services","year":"2004"},{"key":"10.1016\/j.jocd.2008.02.002_bib5","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1007\/BF01623453","article-title":"Who are candidates for prevention and treatment for osteoporosis?","volume":"7","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib6","series-title":"America's Bone Health: The State of Osteoporosis and Low Bone Mass in Our Nation","year":"2002"},{"key":"10.1016\/j.jocd.2008.02.002_bib7","doi-asserted-by":"crossref","first-page":"427","DOI":"10.1007\/BF01626603","article-title":"Direct clinical and welfare costs of osteoporotic fractures in elderly men and women","volume":"5","author":"Randell","year":"1995","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib8","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1007\/s00198-006-0172-4","article-title":"An estimate of the worldwide prevalence and disability associated with osteoporotic fractures","volume":"17","author":"Johnell","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib9","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1053\/berh.2002.0264","article-title":"Epidemiology of osteoporosis","volume":"16","author":"Jordan","year":"2002","journal-title":"Best Pract Res Clin Rheumatol"},{"key":"10.1016\/j.jocd.2008.02.002_bib10","doi-asserted-by":"crossref","first-page":"377","DOI":"10.1016\/8756-3282(94)90813-3","article-title":"Costs and health effects of osteoporotic fractures","volume":"15","author":"Chrischilles","year":"1994","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2008.02.002_bib11","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1359\/jbmr.1997.12.1.16","article-title":"Fractures attributable to osteoporosis: report from the National Osteoporosis Foundation","volume":"12","author":"Melton","year":"1997","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib12","doi-asserted-by":"crossref","first-page":"2445","DOI":"10.1001\/archinte.1989.00390110045010","article-title":"Lifetime risks of hip, Colles', or vertebral fracture and coronary heart disease among white postmenopausal women","volume":"149","author":"Cummings","year":"1989","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib13","doi-asserted-by":"crossref","first-page":"390","DOI":"10.1007\/BF01623782","article-title":"Guidelines for diagnosis and management of osteoporosis. The European Foundation for Osteoporosis and Bone Disease","volume":"7","author":"Kanis","year":"1997","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib14","series-title":"Osteoporosis in Men: The Effects of Gender on Skeletal Health","first-page":"15","article-title":"Economic impact of fractures","author":"Tosteson","year":"1999"},{"key":"10.1016\/j.jocd.2008.02.002_bib15","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1046\/j.1532-5415.2003.51110.x","article-title":"Estimating hip fracture morbidity, mortality and costs","volume":"51","author":"Braithwaite","year":"2003","journal-title":"J Am Geriatr Soc"},{"key":"10.1016\/j.jocd.2008.02.002_bib16","doi-asserted-by":"crossref","first-page":"2465","DOI":"10.1001\/jama.1941.02820220007002","article-title":"Postmenopausal osteoporosis","volume":"116","author":"Albright","year":"1941","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib17","doi-asserted-by":"crossref","first-page":"133","DOI":"10.1002\/jbmr.5650030203","article-title":"Static and tetracycline-based bone histomorphometric data from 34 normal postmenopausal females","volume":"3","author":"Recker","year":"1988","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib18","doi-asserted-by":"crossref","first-page":"1526","DOI":"10.1359\/jbmr.2000.15.8.1526","article-title":"Biochemical markers of bone turnover, endogenous hormones and the risk of fractures in postmenopausal women: the OFELY study","volume":"15","author":"Garnero","year":"2000","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib19","doi-asserted-by":"crossref","first-page":"13720","DOI":"10.1074\/jbc.M410995200","article-title":"Negative regulation of RANKL-induced osteoclastic differentiation in RAW264.7 Cells by estrogen and phytoestrogens","volume":"280","author":"Garcia Palacios","year":"2005","journal-title":"J\u00a0Biol Chem"},{"key":"10.1016\/j.jocd.2008.02.002_bib20","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1016\/j.cell.2007.07.025","article-title":"Estrogen prevents bone loss via estrogen receptor alpha and induction of Fas ligand in osteoclasts","volume":"130","author":"Nakamura","year":"2007","journal-title":"Cell"},{"key":"10.1016\/j.jocd.2008.02.002_bib21","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1016\/j.bbrc.2004.11.097","article-title":"Mechanisms of sex steroid effects on bone","volume":"328","author":"Syed","year":"2005","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jocd.2008.02.002_bib22","first-page":"143","article-title":"Oestrogen action on bone cells","volume":"2","author":"Krassas","year":"2001","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.jocd.2008.02.002_bib23","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1002\/jbmr.5650110307","article-title":"Increased bone turnover in late postmenopausal women is a major determinant of osteoporosis","volume":"11","author":"Garnero","year":"1996","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib24","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1152\/physrev.2001.81.1.419","article-title":"Sex steroids and bone","volume":"81","author":"Compston","year":"2001","journal-title":"Physiol Rev"},{"key":"10.1016\/j.jocd.2008.02.002_bib25","doi-asserted-by":"crossref","first-page":"2250","DOI":"10.1056\/NEJMra053077","article-title":"Bone quality\u2014the material and structural basis of bone strength and fragility","volume":"354","author":"Seeman","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib26","doi-asserted-by":"crossref","first-page":"309","DOI":"10.1016\/S0092-8674(00)80209-3","article-title":"Osteoprotegerin: a novel secreted protein involved in the regulation of bone density","volume":"89","author":"Simonet","year":"1997","journal-title":"Cell"},{"key":"10.1016\/j.jocd.2008.02.002_bib27","doi-asserted-by":"crossref","first-page":"1260","DOI":"10.1101\/gad.12.9.1260","article-title":"Osteoprotegerin-deficient mice develop early onset osteoporosis and arterial calcification","volume":"12","author":"Bucay","year":"1998","journal-title":"Genes Dev"},{"key":"10.1016\/j.jocd.2008.02.002_bib28","doi-asserted-by":"crossref","first-page":"463","DOI":"10.1084\/jem.192.4.463","article-title":"Osteoprotegerin reverses osteoporosis by inhibiting endosteal osteoclasts and prevents vascular calcification by blocking a process resembling osteoclastogenesis","volume":"192","author":"Min","year":"2000","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib29","doi-asserted-by":"crossref","first-page":"165","DOI":"10.1016\/S0092-8674(00)81569-X","article-title":"Osteoprotegerin ligand is a cytokine that regulates osteoclast differentiation and activation","volume":"93","author":"Lacey","year":"1998","journal-title":"Cell"},{"key":"10.1016\/j.jocd.2008.02.002_bib30","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1210\/endo.139.3.5837","article-title":"Identity of osteoclastogenesis inhibitory factor (OCIF) and osteoprotegerin (OPG): a mechanism by which OPG\/OCIF inhibits osteoclastogenesis in vitro","volume":"139","author":"Yasuda","year":"1998","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2008.02.002_bib31","doi-asserted-by":"crossref","first-page":"3597","DOI":"10.1073\/pnas.95.7.3597","article-title":"Osteoclast differentiation factor is a ligand for osteoprotegerin\/osteoclastogenesis-inhibitory factor and is identical to TRANCE\/RANKL","volume":"95","author":"Yasuda","year":"1998","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocd.2008.02.002_bib32","doi-asserted-by":"crossref","first-page":"527","DOI":"10.1083\/jcb.145.3.527","article-title":"The ligand for osteoprotegerin (OPGL) directly activates mature osteoclasts","volume":"145","author":"Burgess","year":"1999","journal-title":"J Cell Biol"},{"key":"10.1016\/j.jocd.2008.02.002_bib33","doi-asserted-by":"crossref","first-page":"997","DOI":"10.1084\/jem.188.5.997","article-title":"TRANCE is necessary and sufficient for osteoblast-mediated activation of bone resorption in osteoclasts","volume":"188","author":"Fuller","year":"1998","journal-title":"J Exp Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib34","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1073\/pnas.96.7.3540","article-title":"Tumor necrosis factor receptor family member RANK mediates osteoclast differentiation and activation induced by osteoprotegerin ligand","volume":"96","author":"Hsu","year":"1999","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocd.2008.02.002_bib35","doi-asserted-by":"crossref","first-page":"337","DOI":"10.1038\/nature01658","article-title":"Osteoclast differentiation and activation","volume":"423","author":"Boyle","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.jocd.2008.02.002_bib36","doi-asserted-by":"crossref","first-page":"1566","DOI":"10.1073\/pnas.97.4.1566","article-title":"RANK is the intrinsic hematopoietic cell surface receptor that controls osteoclastogenesis and regulation of bone mass and calcium metabolism","volume":"97","author":"Li","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocd.2008.02.002_bib37","doi-asserted-by":"crossref","first-page":"304","DOI":"10.1038\/46303","article-title":"Activated T cells regulate bone loss and joint destruction in adjuvant arthritis through osteoprotegerin ligand","volume":"402","author":"Kong","year":"1999","journal-title":"Nature"},{"key":"10.1016\/j.jocd.2008.02.002_bib38","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1007\/s10735-004-3839-1","article-title":"Detection of osteoprotegerin (OPG) and its ligand (RANKL) mRNA and protein in femur and tibia of the rat","volume":"36","author":"Silvestrini","year":"2005","journal-title":"J Mol Histol"},{"key":"10.1016\/j.jocd.2008.02.002_bib39","doi-asserted-by":"crossref","first-page":"832","DOI":"10.1016\/j.febslet.2004.12.066","article-title":"Phosphodiesterase inhibitors stimulate osteoclast formation via TRANCE\/RANKL expression in osteoblasts: possible involvement of ERK and p38 MAPK pathways","volume":"579","author":"Takami","year":"2005","journal-title":"FEBS Lett"},{"key":"10.1016\/j.jocd.2008.02.002_bib40","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1016\/S0002-9440(10)64556-7","article-title":"Osteoprotegerin ligand modulates murine osteoclast survival in vitro and in vivo","volume":"157","author":"Lacey","year":"2000","journal-title":"Am J Pathol"},{"key":"10.1016\/j.jocd.2008.02.002_bib41","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1172\/JCI200317215","article-title":"Role of RANK ligand in mediating increased bone resorption in early postmenopausal women","volume":"111","author":"Eghbali-Fatourechi","year":"2003","journal-title":"J Clin Invest"},{"key":"10.1016\/j.jocd.2008.02.002_bib42","doi-asserted-by":"crossref","first-page":"4367","DOI":"10.1210\/endo.140.9.7131","article-title":"Estrogen stimulates gene expression and protein production of osteoprotegerin in human osteoblastic cells","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2008.02.002_bib43","doi-asserted-by":"crossref","first-page":"1550","DOI":"10.1210\/jcem.87.4.8397","article-title":"Effect of estrogen versus testosterone on circulating osteoprotegerin and other cytokine levels in normal elderly men","volume":"87","author":"Khosla","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib44","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1210\/endo.142.6.8220","article-title":"17beta-estradiol stimulates expression of osteoprotegerin by a mouse stromal cell line, ST-2, via estrogen receptor-alpha","volume":"142","author":"Saika","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2008.02.002_bib45","doi-asserted-by":"crossref","first-page":"4206","DOI":"10.1210\/jc.2002-021877","article-title":"Raloxifene concurrently stimulates osteoprotegerin and inhibits interleukin-6 production by human trabecular osteoblasts","volume":"88","author":"Viereck","year":"2003","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib46","doi-asserted-by":"crossref","first-page":"7829","DOI":"10.1073\/pnas.130200197","article-title":"Estrogens suppress RANK ligand-induced osteoclast differentiation via a stromal cell independent mechanism involving c-Jun repression","volume":"97","author":"Shevde","year":"2000","journal-title":"Proc Natl Acad Sci U S A"},{"key":"10.1016\/j.jocd.2008.02.002_bib47","doi-asserted-by":"crossref","first-page":"2018","DOI":"10.1016\/S0140-6736(02)08827-X","article-title":"Treatment of postmenopausal osteoporosis","volume":"359","author":"Delmas","year":"2002","journal-title":"Lancet"},{"issue":"Suppl 6","key":"10.1016\/j.jocd.2008.02.002_bib48","doi-asserted-by":"crossref","first-page":"S66","DOI":"10.1007\/s001980070007","article-title":"Markers of bone turnover for monitoring treatment of osteoporosis with antiresorptive drugs","volume":"11","author":"Delmas","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib49","doi-asserted-by":"crossref","first-page":"231","DOI":"10.1210\/jcem.85.1.6267","article-title":"Antifracture efficacy of antiresorptive agents are related to changes in bone density","volume":"85","author":"Wasnich","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib50","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/S8756-3282(00)00301-X","article-title":"How does antiresorptive therapy decrease the risk of fracture in women with osteoporosis?","volume":"27","author":"Delmas","year":"2000","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2008.02.002_bib51","doi-asserted-by":"crossref","first-page":"1051","DOI":"10.1359\/jbmr.2003.18.6.1051","article-title":"Relationship of early changes in bone resorption to the reduction in fracture risk with risedronate","volume":"18","author":"Eastell","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib52","doi-asserted-by":"crossref","first-page":"1250","DOI":"10.1359\/JBMR.040512","article-title":"Change in bone turnover and hip, non-spine, and vertebral fracture in alendronate-treated women: the fracture intervention trial","volume":"19","author":"Bauer","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib53","doi-asserted-by":"crossref","first-page":"1389","DOI":"10.1001\/jama.1996.03540170033029","article-title":"Effects of hormone therapy on bone mineral density: results from the postmenopausal estrogen\/progestin interventions (PEPI) trial. The Writing Group for the PEPI","volume":"276","year":"1996","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib54","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1111\/j.1471-0528.1994.tb13618.x","article-title":"Magnitude and pattern of skeletal response to long term continuous and cyclic sequential oestrogen\/progestin treatment","volume":"101","author":"Pors Nielsen","year":"1994","journal-title":"Br J Obstet Gynaecol"},{"key":"10.1016\/j.jocd.2008.02.002_bib55","first-page":"4462","article-title":"The effect of low dose micronized 17ss-estradiol on bone turnover, sex hormone levels, and side effects in older women: a randomized, double blind, placebo-controlled study","volume":"85","author":"Prestwood","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib56","doi-asserted-by":"crossref","first-page":"897","DOI":"10.7326\/0003-4819-130-11-199906010-00005","article-title":"The effect of low-dose continuous estrogen and progesterone therapy with calcium and vitamin D on bone in elderly women. A randomized, controlled trial","volume":"130","author":"Recker","year":"1999","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib57","doi-asserted-by":"crossref","first-page":"1169","DOI":"10.1056\/NEJM198711053171901","article-title":"Hip fracture and the use of estrogens in postmenopausal women. The Framingham Study","volume":"317","author":"Kiel","year":"1987","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib58","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1007\/BF01623654","article-title":"Fracture protection provided by long-term estrogen treatment","volume":"5","author":"Maxim","year":"1995","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib59","doi-asserted-by":"crossref","first-page":"28","DOI":"10.7326\/0003-4819-95-1-28","article-title":"Menopausal estrogen therapy and hip fractures","volume":"95","author":"Paganini-Hill","year":"1981","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib60","doi-asserted-by":"crossref","first-page":"2891","DOI":"10.1001\/jama.285.22.2891","article-title":"Hormone replacement therapy and prevention of nonvertebral fractures: a meta-analysis of randomized trials","volume":"285","author":"Torgerson","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib61","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1001\/jama.288.3.321","article-title":"Risks and benefits of estrogen plus progestin in healthy postmenopausal women: principal results from the Women's Health Initiative randomized controlled trial","volume":"288","author":"Rossouw","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib62","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1001\/jama.282.7.637","article-title":"Reduction of vertebral fracture risk in postmenopausal women with osteoporosis treated with raloxifene: results from a 3-year randomized clinical trial. Multiple Outcomes of Raloxifene Evaluation (MORE) Investigators","volume":"282","author":"Ettinger","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib63","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1056\/NEJMoa062462","article-title":"Effects of raloxifene on cardiovascular events and breast cancer in postmenopausal women","volume":"355","author":"Barrett-Connor","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib64","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1023\/A:1006478317173","article-title":"Continued breast cancer risk reduction in postmenopausal women treated with raloxifene: 4-year results from the MORE trial. Multiple outcomes of raloxifene evaluation","volume":"65","author":"Cauley","year":"2001","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.jocd.2008.02.002_bib65","doi-asserted-by":"crossref","first-page":"2189","DOI":"10.1001\/jama.281.23.2189","article-title":"The effect of raloxifene on risk of breast cancer in postmenopausal women: results from the MORE randomized trial. Multiple Outcomes of Raloxifene Evaluation","volume":"281","author":"Cummings","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib66","series-title":"Bisphosphonates in Bone Disease: From the Laboratory to the Patient","author":"Fleisch","year":"2000"},{"key":"10.1016\/j.jocd.2008.02.002_bib67","series-title":"Bone Health and Osteoporosis: A Report of the Surgeon General","article-title":"Chapter 9: Prevention and treatment for those who have bone disease","author":"U.S. Department of Health and Human Services","year":"2004"},{"key":"10.1016\/j.jocd.2008.02.002_bib68","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1056\/NEJM199802193380801","article-title":"Prevention of bone loss with alendronate in postmenopausal women under 60 years of age. Early Postmenopausal Intervention Cohort Study Group","volume":"338","author":"Hosking","year":"1998","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib69","doi-asserted-by":"crossref","first-page":"253","DOI":"10.7326\/0003-4819-128-4-199802150-00001","article-title":"Alendronate prevents postmenopausal bone loss in women without osteoporosis. A double-blind, randomized, controlled trial. Alendronate Osteoporosis Prevention Study Group","volume":"128","author":"McClung","year":"1998","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib70","doi-asserted-by":"crossref","first-page":"1535","DOI":"10.1016\/S0140-6736(96)07088-2","article-title":"Randomised trial of effect of alendronate on risk of fracture in women with existing vertebral fractures. Fracture Intervention Trial Research Group","volume":"348","author":"Black","year":"1996","journal-title":"Lancet"},{"key":"10.1016\/j.jocd.2008.02.002_bib71","doi-asserted-by":"crossref","first-page":"4118","DOI":"10.1210\/jcem.85.11.6953","article-title":"Fracture risk reduction with alendronate in women with osteoporosis: the Fracture Intervention Trial. FIT Research Group","volume":"85","author":"Black","year":"2000","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib72","doi-asserted-by":"crossref","first-page":"2077","DOI":"10.1001\/jama.280.24.2077","article-title":"Effect of alendronate on risk of fracture in women with low bone density but without vertebral fractures: results from the Fracture Intervention Trial","volume":"280","author":"Cummings","year":"1998","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib73","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1007\/PL00004171","article-title":"Multinational, placebo-controlled, randomized trial of the effects of alendronate on bone density and fracture risk in postmenopausal women with low bone mass: results of the FOSIT study. Foxamax International Trial Study Group","volume":"9","author":"Pols","year":"1999","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib74","first-page":"396","article-title":"Risedronate increases bone mass in an early postmenopausal population: two years of treatment plus one year of follow-up","volume":"83","author":"Mortensen","year":"1998","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib75","doi-asserted-by":"crossref","first-page":"1344","DOI":"10.1001\/jama.282.14.1344","article-title":"Effects of risedronate treatment on vertebral and nonvertebral fractures in women with postmenopausal osteoporosis: a randomized controlled trial. Vertebral Efficacy With Risedronate Therapy (VERT) Study Group","volume":"282","author":"Harris","year":"1999","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib76","doi-asserted-by":"crossref","first-page":"83","DOI":"10.1007\/s001980050010","article-title":"Randomized trial of the effects of risedronate on vertebral fractures in women with established postmenopausal osteoporosis. Vertebral Efficacy with Risedronate Therapy (VERT) Study Group","volume":"11","author":"Reginster","year":"2000","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib77","doi-asserted-by":"crossref","first-page":"333","DOI":"10.1056\/NEJM200102013440503","article-title":"Effect of risedronate on the risk of hip fracture in elderly women. Hip Intervention Program Study Group","volume":"344","author":"McClung","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib78","doi-asserted-by":"crossref","first-page":"1241","DOI":"10.1359\/JBMR.040325","article-title":"Effects of oral ibandronate administered daily or intermittently on fracture risk in postmenopausal osteoporosis","volume":"19","author":"Chesnut","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib79","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1007\/s00198-004-1602-9","article-title":"Daily and intermittent oral ibandronate normalize bone turnover and provide significant reduction in vertebral fracture risk: results from the BONE study","volume":"15","author":"Delmas","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib80","doi-asserted-by":"crossref","first-page":"1315","DOI":"10.1359\/JBMR.050313","article-title":"Monthly oral ibandronate therapy in postmenopausal osteoporosis: 1-year results from the MOBILE study","volume":"20","author":"Miller","year":"2005","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib81","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1016\/j.bone.2004.01.007","article-title":"Efficacy and safety of ibandronate given by intravenous injection once every 3 months","volume":"34","author":"Adami","year":"2004","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2008.02.002_bib82","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1056\/NEJMoa011807","article-title":"Intravenous zoledronic acid in postmenopausal women with low bone mineral density","volume":"346","author":"Reid","year":"2002","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib83","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1056\/NEJMoa067312","article-title":"Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis","volume":"356","author":"Black","year":"2007","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib84","doi-asserted-by":"crossref","first-page":"1799","DOI":"10.1056\/NEJMoa074941","article-title":"Zoledronic acid and clinical fractures and mortality after hip fracture","volume":"357","author":"Lyles","year":"2007","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib85","doi-asserted-by":"crossref","first-page":"1016","DOI":"10.1056\/NEJM199610033351403","article-title":"Esophagitis associated with the use of alendronate","volume":"335","author":"de Groen","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib86","doi-asserted-by":"crossref","first-page":"685","DOI":"10.2165\/00003495-200161050-00013","article-title":"Risedronate: a review of its pharmacological properties and clinical use in resorptive bone disease","volume":"61","author":"Dunn","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.jocd.2008.02.002_bib87","doi-asserted-by":"crossref","first-page":"999","DOI":"10.2165\/00003495-200161070-00010","article-title":"Alendronate: an update of its use in osteoporosis","volume":"61","author":"Sharpe","year":"2001","journal-title":"Drugs"},{"key":"10.1016\/j.jocd.2008.02.002_bib88","doi-asserted-by":"crossref","first-page":"2278","DOI":"10.1056\/NEJMp068157","article-title":"Osteonecrosis of the jaw\u2014do bisphosphonates pose a risk?","volume":"355","author":"Bilezikian","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib89","doi-asserted-by":"crossref","first-page":"753","DOI":"10.7326\/0003-4819-144-10-200605160-00009","article-title":"Narrative [corrected] review: bisphosphonates and osteonecrosis of the jaws","volume":"144","author":"Woo","year":"2006","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib90","doi-asserted-by":"crossref","first-page":"395","DOI":"10.1016\/j.jcms.2005.07.007","article-title":"Does avascular necrosis of the jaws in cancer patients only occur following treatment with bisphosphonates?","volume":"33","author":"Lenz","year":"2005","journal-title":"J Craniomaxillofac Surg"},{"key":"10.1016\/j.jocd.2008.02.002_bib91","doi-asserted-by":"crossref","first-page":"8580","DOI":"10.1200\/JCO.2005.02.8670","article-title":"Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors","volume":"23","author":"Bamias","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocd.2008.02.002_bib92","doi-asserted-by":"crossref","first-page":"1567","DOI":"10.1016\/j.joms.2005.07.010","article-title":"Bisphosphonate-induced exposed bone (osteonecrosis\/osteopetrosis) of the jaws: risk factors, recognition, prevention, and treatment","volume":"63","author":"Marx","year":"2005","journal-title":"J Oral Maxillofac Surg"},{"key":"10.1016\/j.jocd.2008.02.002_bib93","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.2174\/092986730611220401164504","article-title":"Calcitonin","volume":"6","author":"Sexton","year":"1999","journal-title":"Curr Med Chem"},{"key":"10.1016\/j.jocd.2008.02.002_bib94","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1016\/S0002-9343(00)00490-3","article-title":"A randomized trial of nasal spray salmon calcitonin in postmenopausal women with established osteoporosis: the prevent recurrence of osteoporotic fractures study. PROOF Study Group","volume":"109","author":"Chesnut","year":"2000","journal-title":"Am J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib95","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1056\/NEJMoa022436","article-title":"The effects of strontium ranelate on the risk of vertebral fracture in women with postmenopausal osteoporosis","volume":"350","author":"Meunier","year":"2004","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib96","first-page":"2060","article-title":"Strontium ranelate: dose-dependent effects in established postmenopausal vertebral osteoporosis\u2014a 2-year randomized placebo controlled trial","volume":"87","author":"Meunier","year":"2002","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib97","doi-asserted-by":"crossref","first-page":"2816","DOI":"10.1210\/jc.2004-1774","article-title":"Strontium ranelate reduces the risk of nonvertebral fractures in postmenopausal women with osteoporosis: Treatment of Peripheral Osteoporosis (TROPOS) study","volume":"90","author":"Reginster","year":"2005","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib98","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/S0014-2999(02)02040-X","article-title":"In vitro effects of S12911-2 on osteoclast function and bone marrow macrophage differentiation","volume":"450","author":"Baron","year":"2002","journal-title":"Eur J Pharmacol"},{"key":"10.1016\/j.jocd.2008.02.002_bib99","doi-asserted-by":"crossref","first-page":"517","DOI":"10.1016\/8756-3282(96)00080-4","article-title":"The divalent strontium salt S12911 enhances bone cell replication and bone formation in vitro","volume":"18","author":"Canalis","year":"1996","journal-title":"Bone"},{"key":"10.1016\/j.jocd.2008.02.002_bib100","doi-asserted-by":"crossref","first-page":"1082","DOI":"10.1359\/jbmr.2003.18.6.1082","article-title":"S 12911-2 inhibits osteoclastic bone resorption in vitro","volume":"18","author":"Takahashi","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib101","doi-asserted-by":"crossref","first-page":"1434","DOI":"10.1056\/NEJM200105103441904","article-title":"Effect of parathyroid hormone (1-34) on fractures and bone mineral density in postmenopausal women with osteoporosis","volume":"344","author":"Neer","year":"2001","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib102","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/S1043-2760(01)00460-X","article-title":"Reconstructing the skeleton with intermittent parathyroid hormone","volume":"12","author":"Seeman","year":"2001","journal-title":"Trends Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib103","doi-asserted-by":"crossref","first-page":"1846","DOI":"10.1359\/jbmr.2001.16.10.1846","article-title":"Effects of daily treatment with parathyroid hormone on bone microarchitecture and turnover in patients with osteoporosis: a paired biopsy study","volume":"16","author":"Dempster","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib104","doi-asserted-by":"crossref","first-page":"688","DOI":"10.1210\/er.2004-0006","article-title":"Parathyroid hormone and teriparatide for the treatment of osteoporosis: a review of the evidence and suggested guidelines for its use","volume":"26","author":"Hodsman","year":"2005","journal-title":"Endocr Rev"},{"key":"10.1016\/j.jocd.2008.02.002_bib105","doi-asserted-by":"crossref","first-page":"2414","DOI":"10.1001\/archinte.165.20.2414","article-title":"Compliance with osteoporosis medications","volume":"165","author":"Solomon","year":"2005","journal-title":"Arch Intern Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib106","doi-asserted-by":"crossref","first-page":"1645","DOI":"10.1007\/s00198-006-0179-x","article-title":"Compliance with drug therapy for postmenopausal osteoporosis","volume":"17","author":"Weycker","year":"2006","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib107","doi-asserted-by":"crossref","first-page":"271","DOI":"10.1016\/j.maturitas.2004.02.005","article-title":"Compliance with drug therapies for the treatment and prevention of osteoporosis","volume":"48","author":"McCombs","year":"2004","journal-title":"Maturitas"},{"key":"10.1016\/j.jocd.2008.02.002_bib108","doi-asserted-by":"crossref","first-page":"1003","DOI":"10.1007\/s00198-004-1652-z","article-title":"The impact of compliance with osteoporosis therapy on fracture rates in actual practice","volume":"15","author":"Caro","year":"2004","journal-title":"Osteoporos Int"},{"key":"10.1016\/j.jocd.2008.02.002_bib109","doi-asserted-by":"crossref","first-page":"1013","DOI":"10.4065\/81.8.1013","article-title":"Adherence to bisphosphonate therapy and fracture rates in osteoporotic women: relationship to vertebral and nonvertebral fractures from 2 US claims databases","volume":"81","author":"Siris","year":"2006","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.jocd.2008.02.002_bib110","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1359\/jbmr.2003.18.5.852","article-title":"Sustained antiresorptive effects after a single treatment with human recombinant osteoprotegerin (OPG): a pharmacodynamic and pharmacokinetic analysis in rats","volume":"18","author":"Capparelli","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib111","first-page":"S523","article-title":"The pharmacokinetics and pharmacodynamics of OPG following single dose administration in cynomolgus monkeys","volume":"14","author":"Martin","year":"1999","journal-title":"J. Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib112","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1023\/A:1011229324412","article-title":"The effects of osteoprotegerin on the mechanical properties of rat bone","volume":"12","author":"Ross","year":"2001","journal-title":"J Mater Sci Mater Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib113","first-page":"S304","article-title":"RANKL inhibition with OPG preserves bone density and trabecular architecture in ovariectomized rats","volume":"21","author":"Li","year":"2006","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib114","doi-asserted-by":"crossref","first-page":"4295","DOI":"10.1210\/endo.142.10.8437","article-title":"OPG and PTH-(1-34) have additive effects on bone density and mechanical strength in osteopenic ovariectomized rats","volume":"142","author":"Kostenuik","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2008.02.002_bib115","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1359\/jbmr.2001.16.2.348","article-title":"The effect of a single dose of osteoprotegerin in postmenopausal women","volume":"16","author":"Bekker","year":"2001","journal-title":"J\u00a0Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib116","first-page":"S96","article-title":"Bone mineral density is increased following monthly administration of AMG 162 in cynomologus monkeys","volume":"18","author":"Atkinson","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib117","unstructured":"Peterson MC, Stouch BJ, Chen D, et\u00a0al. AMG 162, a fully human monoclonal antibody against receptor activator of NF-kappa B ligand (RANKL), rapidly and profoundly suppresses bone resorption in cynomolgus monkey IBMS\/JSBMR Joint Meeting. Osaka, Japan; 2003."},{"key":"10.1016\/j.jocd.2008.02.002_bib118","first-page":"S72","article-title":"Denosumab (AMG 162, a fully human RANKL antibody) increases cortical and cancellous bone mass and density in aged ovariectomized cynomologus monkeys","volume":"21","author":"Ominsky","year":"2006","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.jocd.2008.02.002_bib119","first-page":"S23","article-title":"Denosumab (AMG 162), a fully human RANKL antibody, improves cortical and cancellous bone mass and bone strength in ovariectomized cynomolgus monkeys","volume":"22","author":"Ominsky","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib120","first-page":"S166","article-title":"AMG 162 maintains serum concentration for up to 9 months following a single subcutaneous dose in healthy postmenopausal women","volume":"18","author":"Peterson","year":"2003","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib121","doi-asserted-by":"crossref","first-page":"1059","DOI":"10.1359\/JBMR.040305","article-title":"A single-dose placebo-controlled study of AMG 162, a fully human monoclonal antibody to RANKL, in postmenopausal women","volume":"19","author":"Bekker","year":"2004","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib122","doi-asserted-by":"crossref","first-page":"821","DOI":"10.1056\/NEJMoa044459","article-title":"Denosumab in postmenopausal women with low bone mineral density","volume":"354","author":"McClung","year":"2006","journal-title":"N Engl J Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib123","doi-asserted-by":"crossref","first-page":"1832","DOI":"10.1359\/jbmr.070809","article-title":"Two-year treatment with denosumab (AMG 162) in a randomized phase 2 study of postmenopausal women with low BMD","volume":"22","author":"Lewiecki","year":"2007","journal-title":"J Bone Miner Res"},{"issue":"Suppl 1","key":"10.1016\/j.jocd.2008.02.002_bib124","first-page":"S58","article-title":"Effect of denosumab on bone mineral density and bone turnover markers: 48-month results","volume":"22","author":"Miller","year":"2007","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib125","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1093\/ndt\/16.3.479","article-title":"Glucocorticoid decreases circulating osteoprotegerin (OPG): possible mechanism for glucocorticoid induced osteoporosis","volume":"16","author":"Sasaki","year":"2001","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.jocd.2008.02.002_bib126","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/00042737-200311000-00003","article-title":"Effect of systemic glucocorticoid therapy on bone metabolism and the osteoprotegerin system in patients with active Crohn's disease","volume":"15","author":"von Tirpitz","year":"2003","journal-title":"Eur J\u00a0Gastroenterol Hepatol"},{"key":"10.1016\/j.jocd.2008.02.002_bib127","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1002\/jcb.10490","article-title":"Mediators of the biphasic responses of bone to intermittent and continuously administered parathyroid hormone","volume":"89","author":"Locklin","year":"2003","journal-title":"J Cell Biochem"},{"key":"10.1016\/j.jocd.2008.02.002_bib128","first-page":"268","article-title":"The OPG\/RANKL\/RANK system in metabolic bone diseases","volume":"4","author":"Hofbauer","year":"2004","journal-title":"J Musculoskelet Neuronal Interact"},{"key":"10.1016\/j.jocd.2008.02.002_bib129","doi-asserted-by":"crossref","first-page":"490","DOI":"10.1001\/jama.292.4.490","article-title":"Clinical implications of the osteoprotegerin\/RANKL\/RANK system for bone and vascular diseases","volume":"292","author":"Hofbauer","year":"2004","journal-title":"JAMA"},{"key":"10.1016\/j.jocd.2008.02.002_bib130","first-page":"16","article-title":"Hormone- and chemotherapy-induced bone loss in breast cancer","volume":"18","author":"Coleman","year":"2004","journal-title":"Oncology (Williston Park)"},{"key":"10.1016\/j.jocd.2008.02.002_bib131","first-page":"2787","article-title":"Bone loss in men with prostate cancer treated with gonadotropin-releasing hormone agonists","volume":"86","author":"Stoch","year":"2001","journal-title":"J Clin Endocrinol Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib132","first-page":"11","article-title":"Pathophysiology and implications of cancer treatment-induced bone loss","volume":"18","author":"Theriault","year":"2004","journal-title":"Oncology (Huntingt)"},{"key":"10.1016\/j.jocd.2008.02.002_bib133","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1006\/bbrc.2000.4130","article-title":"Effects of immunosuppressants on receptor activator of NF-kappaB ligand and osteoprotegerin production by human osteoblastic and coronary artery smooth muscle cells","volume":"280","author":"Hofbauer","year":"2001","journal-title":"Biochem Biophys Res Commun"},{"key":"10.1016\/j.jocd.2008.02.002_bib134","doi-asserted-by":"crossref","first-page":"C1126","DOI":"10.1152\/ajpcell.2000.278.6.C1126","article-title":"Mechanical strain inhibits expression of osteoclast differentiation factor by murine stromal cells","volume":"278","author":"Rubin","year":"2000","journal-title":"Am J Physiol Cell Physiol"},{"key":"10.1016\/j.jocd.2008.02.002_bib135","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1002\/path.1199","article-title":"RANK ligand is a prerequisite for cancer-associated osteolytic lesions","volume":"198","author":"Kitazawa","year":"2002","journal-title":"J Pathol"},{"key":"10.1016\/j.jocd.2008.02.002_bib136","doi-asserted-by":"crossref","first-page":"584","DOI":"10.1038\/nrc867","article-title":"Metastasis to bone: causes, consequences and therapeutic opportunities","volume":"2","author":"Mundy","year":"2002","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.jocd.2008.02.002_bib137","doi-asserted-by":"crossref","first-page":"1655","DOI":"10.1056\/NEJMra030831","article-title":"Mechanisms of bone metastasis","volume":"350","author":"Roodman","year":"2004","journal-title":"N Engl J\u00a0Med"},{"key":"10.1016\/j.jocd.2008.02.002_bib138","doi-asserted-by":"crossref","first-page":"4382","DOI":"10.1210\/endo.140.10.7034","article-title":"Stimulation of osteoprotegerin ligand and inhibition of osteoprotegerin production by glucocorticoids in human osteoblastic lineage cells: potential paracrine mechanisms of glucocorticoid-induced osteoporosis","volume":"140","author":"Hofbauer","year":"1999","journal-title":"Endocrinology"},{"key":"10.1016\/j.jocd.2008.02.002_bib139","doi-asserted-by":"crossref","first-page":"518","DOI":"10.1016\/S0736-0266(00)00057-7","article-title":"Osteoprotegerin ameliorates sciatic nerve crush induced bone loss","volume":"19","author":"Bateman","year":"2001","journal-title":"J\u00a0Orthop Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib140","doi-asserted-by":"crossref","first-page":"14","DOI":"10.1007\/s774-002-8441-x","article-title":"Osteoclastogenesis inhibitory factor\/osteoprotegerin ameliorates the decrease in both bone mineral density and bone strength in immobilized rats","volume":"20","author":"Mochizuki","year":"2002","journal-title":"J Bone Miner Metab"},{"key":"10.1016\/j.jocd.2008.02.002_bib141","first-page":"S148","article-title":"Osteoprotegerin (OPG) prevents bone loss in a rat model of glucocorticoid-induced osteopenia","volume":"16","author":"Morony","year":"2001","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib142","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib143","first-page":"7883","article-title":"Soluble receptor activator of nuclear factor kappaB Fc diminishes prostate cancer progression in bone","volume":"63","author":"Zhang","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib144","first-page":"287","article-title":"Recombinant osteoprotegerin decreases tumor burden and increases survival in a murine model of multiple myeloma","volume":"63","author":"Vanderkerken","year":"2003","journal-title":"Cancer Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib145","doi-asserted-by":"crossref","first-page":"1221","DOI":"10.1158\/1078-0432.CCR-05-1933","article-title":"A study of the biological receptor activator of nuclear factor-kappaB ligand inhibitor, denosumab, in patients with multiple myeloma or bone metastases from breast cancer","volume":"12","author":"Body","year":"2006","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.jocd.2008.02.002_bib146","doi-asserted-by":"crossref","first-page":"8562","DOI":"10.1200\/jco.2006.24.18_suppl.8562","article-title":"A randomized trial of denosumab (AMG 162) versus intravenous (IV) bisphosphonates (BP) in cancer patients (pts) with bone metastases (BM) on established IV BP and evidence of elevated bone resorption","volume":"24","author":"Suarez","year":"2006","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocd.2008.02.002_bib147","doi-asserted-by":"crossref","first-page":"4431","DOI":"10.1200\/JCO.2007.11.8604","article-title":"Randomized active-controlled phase II study of denosumab efficacy and safety in patients with breast cancer-related bone metastases","volume":"25","author":"Lipton","year":"2007","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.jocd.2008.02.002_bib148","article-title":"RANKL inhibition with denosumab reduces progression of bone erosions in patients with rheumatoid arthritis: month 6 MRI results","volume":"54","author":"Cohen","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl II","key":"10.1016\/j.jocd.2008.02.002_bib149","first-page":"89","article-title":"The RANKL inhibitor denosumab reduces progression of the Total Sharp Score and bone erosions in patients with rheumatoid arthritis: x-ray results at 12 months","volume":"66","author":"van der Heijde","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"Suppl 9","key":"10.1016\/j.jocd.2008.02.002_bib150","first-page":"S225","article-title":"RANKL inhibition with denosumab decreases markers of bone and cartilage turnover in patients with rheumatoid arthritis","volume":"54","author":"Lane","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"Suppl 1","key":"10.1016\/j.jocd.2008.02.002_bib151","first-page":"S59","article-title":"Denosumab increases bone mineral density in patients with rheumatoid arthritis: 12-month results","volume":"22","author":"Dore","year":"2007","journal-title":"J Bone Miner Res"}],"container-title":["Journal of Clinical Densitometry"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109469500800019X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S109469500800019X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T21:35:08Z","timestamp":1761082508000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S109469500800019X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2008,4]]},"references-count":151,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2008,4]]}},"alternative-id":["S109469500800019X"],"URL":"https:\/\/doi.org\/10.1016\/j.jocd.2008.02.002","relation":{},"ISSN":["1094-6950"],"issn-type":[{"value":"1094-6950","type":"print"}],"subject":[],"published":{"date-parts":[[2008,4]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Clinical Potential of RANKL Inhibition for the Management of Postmenopausal Osteoporosis and Other Metabolic Bone Diseases","name":"articletitle","label":"Article Title"},{"value":"Journal of Clinical Densitometry","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jocd.2008.02.002","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2008 The International Society for Clinical Densitometry. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}